Thursday, February 22, 2018
 
 
Company News: Page (1) of 1 - 01/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
-- Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1)-- Data ...
(January 16, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:USA,Medicine,Disease,healthcare,Therapy,Technology,Surgery,Medication,Vitamins/Nutrition,Womens Health,Physician,Nurse,Health Technologist,Science,Medical Technology,Medical,Adults,Other,Medical Professionals,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • Driven by Boomers, Consumer-Driven Genetic Testing Forecasted to Reach $310 Million
  • Global Mobile Medical Apps Market to Reach $11.22 Billion by 2025, Reports BIS Research
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry

    Cancer
  • argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
  • CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting
  • Varian Acquires Evinance Innovation, Inc.
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines